STAT+: The loophole in Trump’s obesity drug deal with Eli Lilly and Novo Nordisk

The Trump administration's deal with Eli Lilly and Novo Nordisk on GLP-1 drugs aimed for lower Medicare/Medicaid prices in exchange for higher sales volume, but companies secured higher sales without lowering prices in some cases. The $245 monthly price was contingent on private insurers covering the drugs with a $50 copay, a condition not publicly disclosed by the administration.